市場調査レポート
商品コード
1462311
PF-07923568市場:市場規模、予測、新たな洞察-2032年PF-07923568 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
PF-07923568市場:市場規模、予測、新たな洞察-2032年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
PF-07923568は、経口で生物学的に利用可能な呼吸器合胞体ウイルス(RSV)の融合阻害剤であり、Reviral社の物性指向型ヒットプロファイリングエクササイズに由来するヒットに基づくリード最適化プロセスを経て同定されました。この最適化には、前臨床および臨床評価段階での化合物の利用に加え、最適化段階での医薬品化学およびウイルス学との共同研究を行う多くの契約機関との共同研究が含まれます。
この化合物は、RSVウイルスと宿主細胞との融合を阻害する経口投与阻害剤であり、現在、成人および小児を対象とした第II相臨床開発段階にあります。
今後数年間で、呼吸器合胞体ウイルス(RSV)の市場シナリオは、世界中の広範な調査とヘルスケア支出の増加により変化するとみられます。各社は、病態を治療/改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、PF-07923568の優位性に影響を与える可能性のある機会を模索しています。RSVに対する他の新興製品がPF-07923568に厳しい市場競争を与えることが予想され、近い将来に後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国における呼吸器合胞体ウイルス(RSV)治療薬のPF-07923568市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"PF-07923568 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about PF-07923568 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the PF-07923568 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PF-07923568 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PF-07923568 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
PF-07923568 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation.
It is an orally administered inhibitor designed to block fusion of the RSV virus to the host cell currently in Phase II clinical development for both adult and pediatric populations.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PF-07923568 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of PF-07923568 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of PF-07923568 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.